Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
News|Podcasts|September 21, 2026
ACT Brief: Patient-Site Trust and AI Role, Platform Approach to Scale, Gene Therapy for Pediatric Disease
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a
video interview prior to DPHARM 2026 , Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation, from building trust between patients and sites to where AI may and may not have a role in that relationship. Understanding that distinction—where human connection matters most versus where technology can help—is critical to genuine patient engagement. - In a
contributed article , Jason Makuch of IQVIA examined how only one in five life sciences organizations are scaling AI and seeing measurable value, because disconnected AI tools create silos instead of reducing them. A platform-based approach connects AI across workflows and governance, bringing AI into the tools employees already use rather than requiring them to switch between systems. - The
FDA approved Fayuvi as the first therapy for Sanfilippo syndrome type A , a rare genetic disease that progressively damages children's brains and nervous systems. Administered as a single infusion using gene therapy to deliver a missing enzyme, Fayuvi-treated patients in clinical trials maintained or improved cognitive function compared to an untreated historical comparison group, diverging from the expected disease course of decline during early childhood.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Trending on Applied Clinical Trials Online
1
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
2
Better Site Training Starts With Five Simple Questions
3
How Routine Lab Markers Can Stand In for Missing Functional Status Data
4
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
5